Company Valuation: HLS Therapeutics Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 384.6 235.2 95.92 86.84 109.9 94.6 - -
Change - -38.85% -59.22% -9.47% 26.6% -13.95% - -
Enterprise Value (EV) 384.6 235.2 95.92 86.84 109.9 94.6 94.6 94.6
Change - -38.85% -59.22% -9.47% 26.6% -13.95% 0% 0%
P/E -28.9x -9.95x -3.52x -4.41x -9.01x -15.1x -101x 43.2x
PBR - 1.88x - 1.22x - 1.64x 1.59x -
PEG - -0.1x -0.2x 0.2x 0.2x 0.3x 1.2x -0x
Capitalization / Revenue 6.41x 3.83x 1.52x 1.53x 1.98x 1.63x 1.47x 1.23x
EV / Revenue 0x 0x 0x 0x 0x 1.63x 1.47x 1.23x
EV / EBITDA 0x 0x 0x 0x 0x 4.89x 4.03x 2.9x
EV / EBIT -0x -0x -0x -0x -0x -22.5x 63.1x 13.5x
EV / FCF 0x 0x 0x 0x 0x 9.01x - -
FCF Yield 3.27% 7.18% 16.4% 9.2% 15.4% 11.1% - -
Dividend per Share 2 - - 0.7398 - - - - -
Rate of return - - 24.7% - - - - -
EPS 2 -0.41 -0.73 -0.85 -0.62 -0.39 -0.2 -0.03 0.07
Distribution rate - - -87% - - - - -
Net sales 1 60.01 61.47 63.07 56.62 55.5 58.03 64.31 77.2
EBITDA 1 26.33 23.83 21.05 16.65 19.62 19.34 23.45 32.65
EBIT 1 -6.284 -13.5 -10.35 -7.686 -4.106 -4.2 1.5 7
Net income 1 -13.12 -23.6 -27.53 -19.66 -12.43 -6.264 -1.05 2.6
Net Debt - - - - - - - -
Reference price 2 11.853 7.263 2.991 2.731 3.515 3.025 3.025 3.025
Nbr of stocks (in thousands) 32,451 32,384 32,071 31,793 31,274 31,275 - -
Announcement Date 3/17/22 3/16/23 3/14/24 3/13/25 3/12/26 - - -
1USD in Million2USD
Estimates

P/E, Detailed evolution

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
19.36x0.23x13.4x0.41% 95.85B
30.54x0.24x15.26x0.87% 55.54B
43.89x3.1x28.77x1.41% 22.26B
11.21x0.2x4.78x2.68% 8.02B
12.89x0.99x7.97x2.62% 7.46B
6.07x0.1x2.72x4.87% 6.84B
9.58x1.78x5.69x3.44% 6.37B
24.54x1.18x14.55x2.94% 5.31B
10.72x0.12x4.44x4.17% 3.67B
Average 18.76x 0.88x 10.84x 2.6% 23.48B
Weighted average by Cap. 23.60x 0.63x 14.29x 1.16%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. HLS Stock
  4. HLTRF Stock
  5. Valuation HLS Therapeutics Inc.